A Phase 2 interventional study of 350 mg Donepezil Transdermal Patch and Placebo Patch in Irritation/Irritant, sponsored by Teikoku Pharma USA, Inc.. Completed at 7 sites in United States. Open to participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2021-10-28.
Sponsored by Teikoku Pharma USA, Inc. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This study is designed to assess skin tolerability, skin irritation, and adhesion of the 350 mg Donepezil Transdermal Patch (DTP-system), following 3, 7-day applications to 3 specific areas of the body (upper back, upper middle arm, side of torso) of elderly Alzheimer's patients. The total application time for the DTP-system is 21 days.
This is a randomized, placebo-controlled study designed to evaluate skin irritation, skin tolerability, and adhesion of the 350 mg DTP-system following 3 consecutive 7-day applications to 3 specific areas of the body (upper back, upper arm, side of torso) of elderly Alzheimer's patients. The total exposure time for the DTP-system is 21 days.
All patients receive 1 Donepezil Transdermal Patch (DTP-system) and 1 placebo patch, each applied to opposite sides of the body (e.g., placebo patch to the left side of the upper back, and DTP-system to the right side of the upper back). Patients are randomized to receive the active patch to either the left or the right side of the body according to 1 of 6 treatment sequences listed below. The treatment sequence is repeated for the opposite side of the body for a total of 12 treatment sequences (4 patients in each treatment sequence). The patches are applied to one of 3 body locations for 7 days, for a total exposure period of 21 days, according to one of the following sequences:
Patches are applied on Days 1, 8, and 15 according to the randomization schedule. Oral Aricept is taken daily through Day -1, and is re-started on Day 22 or at the time of early termination if before Day 22. Patients are seen in the clinic at Screening and on Days 1, 8, 15, 22, and at the End of Study Visit; for all other daily visits, the patients may be seen either at the clinic or in their residence, provided the assessments are completed as described in the protocol. Skin irritation is assessed immediately upon patch removal and at 1, 24, and 48 hours after removal.
Teikoku Pharma USA, Inc. is the lead sponsor of 8 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
350 mg Donepezil Transdermal Patch (active) and placebo patch, each applied to opposite sides of the upper back.
Drug: 350 mg Donepezil Transdermal Patch · Drug: Placebo Patch
350 mg Donepezil Transdermal Patch (active) and placebo patch, each applied to opposite arms.
Drug: 350 mg Donepezil Transdermal Patch · Drug: Placebo Patch
350 mg Donepezil Transdermal Patch (active) and placebo patch, each applied to opposite sides of torso.
Drug: 350 mg Donepezil Transdermal Patch · Drug: Placebo Patch
Active and placebo patches will be applied to opposite sides for 7 days.
Active and placebo patches will be applied to opposite sides for 7 days.
Skin Irritation (Erythema and Edema)
Erythema and edema were used to determine skin irritation using a modified Draize scale. Score 0 = no erythema/edema; Score 1 = very slight erythema/edema; Score 2 = well-defined erythema/slight edema; Score 3 = moderate to severe erythema/edema; Score 4 = severe erythema/edema.
Time frame: Immediately after patch removal
Skin Irritation (Erythema)
Erythema was used to determine skin irritation using a modified Draize scale. Score 0 = no erythema; Score 1 = very slight erythema; Score 2 = well-defined erythema; Score 3 = moderate to severe erythema; Score 4 = severe erythema.
Time frame: 1, 24, and 48 hours after patch removal (Days 8-10; Days 15-17; Days 22-24)
Skin Irritation (Edema)
Edema was used to determine skin irritation using a modified Draize scale. Score 0 = no edema; Score 1 = very slight edema; Score 2 = slight edema; Score 3 = moderate to severe edema; Score 4 = severe edema.
Time frame: 1, 24, and 48 hours after patch removal (Days 8-10; Days 15-17; Days 22-24)
Skin Irritation (Papules and Vesicles)
Papules and vesicles were assessed according to the following scoring criteria: Score 0 = no evidence of papules or vesicles; Score 1 = few papules or vesicles (\< 10) observed on the skin site; Score 2 = more papules or vesicles (≥ 10) observed on \< 50 % of skin site, diffuse or few clusters; Score 3 = many papules or vesicles observed on ≥ 50% of skin site, diffuse or few clusters; Score 4 = many papules or vesicles observed on \> 50% of skin site, with multiple (\> 3) clusters.
Time frame: Immediately after patch removal
Skin Irritation (Papules and Vesicles)
Papules and vesicles were assessed according to the following scoring criteria: Score 0 = no evidence of papules or vesicles; Score 1 = few papules or vesicles (\< 10) observed on the skin site; Score 2 = more papules or vesicles (≥ 10) observed on \< 50 % of skin site, diffuse or few clusters; Score 3 = many papules or vesicles observed on ≥ 50% of skin site, diffuse or few clusters; Score 4 = many papules or vesicles observed on \> 50% of skin site, with multiple (\> 3) clusters.
Time frame: 1, 24, and 48 hours after patch removal (Days 8-10; Days 15-17; Days 22-24)
Skin Irritation (Other Skin Effects)
Other skin effects were assessed according to the following scoring criteria: Score 0 = no other effects observed; Score 1 = slight glazed appearance; Score 2 = marked glazing; Score 3 = glazing with peeling and cracking; Score 4 = glazing with fissures; Score 5 = film of dried serous exudate covering all or part of the patch site; Score 6 = small petechial erosions and/or scabs.
Time frame: Immediately after patch removal
Skin Irritation (Other Skin Effects)
Other skin effects were assessed according to the following scoring criteria: Score 0 = no other effects observed; Score 1 = slight glazed appearance; Score 2 = marked glazing; Score 3 = glazing with peeling and cracking; Score 4 = glazing with fissures; Score 5 = film of dried serous exudate covering all or part of the patch site; Score 6 = small petechial erosions and/or scabs.
Time frame: 1, 24, and 48 hours after patch removal (Days 8-10; Days 15-17; Days 22-24)
Safety, Tolerability, and Adhesion
See Adverse Event section for Safety assessment. Adhesion was assessed according to the following scoring criteria: Score 0 = approximately \> 90% adhered (essentially no lift off the skin); Score 1 = approximately 75% to \< 90% adhered (some edges only lifting off the skin); Score 2 = approximately 50% to \< 75% adhered (less than half of the system lifting off the skin); Score of 3 = approximately \< 50% adhered but not detached (more than half of the system lifting off the skin without falling off); Score of 4 = Patch-system detached (patch /overlay completely off the skin).
Time frame: Safety was assessed throughout the study. Adhesion was assessed daily and immediately prior to patch removal on Days 8, 15, and 22.
The study was conducted at 7 clinical sites during May and June 2009. Patients received 1 placebo patch and 1 Donepezil Transdermal Patch, each applied to opposite sides of the body. The 7-day patches were applied to 1 of 3 consecutive body locations according to 1 of 6 treatment sequences for a total treatment period of 21 days.
| Milestone | All Participants |
|---|---|
| Started | 49 |
| Completed | 46 |
| Not completed | 3 |
| Withdrew: Adverse event | 1 |
| Withdrew: Death | 1 |
| Withdrew: Protocol violation | 1 |
Erythema and edema were used to determine skin irritation using a modified Draize scale. Score 0 = no erythema/edema; Score 1 = very slight erythema/edema; Score 2 = well-defined erythema/slight edema; Score 3 = moderate to severe erythema/edema; Score 4 = severe erythema/edema.
| units on a scale | Upper Back | Upper Arm | Side of Torso |
|---|---|---|---|
| Erythema, Placebo | 0.9 ± 0.85 | 0.7 ± 0.76 | 1.1 ± 0.89 |
| Erythema, DTP-System | 1.0 ± 0.75 | 0.8 ± 0.75 | 1.0 ± 0.85 |
| Edema, Placebo | 0.6 ± 0.82 | 0.6 ± 0.68 | 0.7 ± 0.71 |
| Edema, DTP-System | 0.6 ± 0.76 | 0.5 ± 0.68 | 0.7 ± 0.73 |
Erythema was used to determine skin irritation using a modified Draize scale. Score 0 = no erythema; Score 1 = very slight erythema; Score 2 = well-defined erythema; Score 3 = moderate to severe erythema; Score 4 = severe erythema.
| units on a scale | Upper Back | Upper Arm | Side of Torso |
|---|---|---|---|
| 1 hour after patch removal, Placebo | 0.8 ± 0.88 | 0.6 ± 0.65 | 0.8 ± 0.82 |
| 1 hour after patch removal, DTP-system | 0.9 ± 0.73 | 0.6 ± 0.64 | 0.7 ± 0.74 |
| 24 hours after patch removal, Placebo | 0.6 ± 0.80 | 0.3 ± 0.52 | 0.7 ± 0.71 |
| 24 hours after patch removal, DTP-system | 0.4 ± 0.62 | 0.4 ± 0.57 | 0.4 ± 0.62 |
| 48 hours after patch removal, Placebo | 0.3 ± 0.54 | 0.2 ± 0.46 | 0.4 ± 0.65 |
| 48 hours after patch removal, DTP-system | 0.2 ± 0.43 | 0.2 ± 0.43 | 0.3 ± 0.59 |
Edema was used to determine skin irritation using a modified Draize scale. Score 0 = no edema; Score 1 = very slight edema; Score 2 = slight edema; Score 3 = moderate to severe edema; Score 4 = severe edema.
| units on a scale | Upper Back | Upper Arm | Side of Torso |
|---|---|---|---|
| 1 hour after patch removal, Placebo | 0.6 ± 0.76 | 0.6 ± 0.68 | 0.6 ± 0.71 |
| 1 hour after patch removal, DTP-system | 0.6 ± 0.73 | 0.4 ± 0.57 | 0.6 ± 0.71 |
| 24 hours after patch removal, Placebo | 0.1 ± 0.41 | 0.2 ± 0.38 | 0.2 ± 0.47 |
| 24 hours after patch removal, DTP-system | 0.1 ± 0.33 | 0.1 ± 0.34 | 0.1 ± 0.40 |
| 48 hours after patch removal, Placebo | 0.0 ± 0.14 | 0.0 ± 0.15 | 0.1 ± 0.25 |
| 48 hours after patch removal, DTP-system | 0.0 ± 0.14 | 0.0 ± 0.15 | 0.0 ± 0.29 |
Papules and vesicles were assessed according to the following scoring criteria: Score 0 = no evidence of papules or vesicles; Score 1 = few papules or vesicles (\< 10) observed on the skin site; Score 2 = more papules or vesicles (≥ 10) observed on \< 50 % of skin site, diffuse or few clusters; Score 3 = many papules or vesicles observed on ≥ 50% of skin site, diffuse or few clusters; Score 4 = many papules or vesicles observed on \> 50% of skin site, with multiple (\> 3) clusters.
| participants | Upper Back | Upper Arm | Side of Torso |
|---|---|---|---|
| Placebo, Score >1 | 9 | 5 | 5 |
| DTP-System, Score >1 | 7 | 2 | 2 |
| Placebo, Score >2 | 2 | 1 | 1 |
| DTP-System, Score >2 | 1 | 0 | 0 |
Papules and vesicles were assessed according to the following scoring criteria: Score 0 = no evidence of papules or vesicles; Score 1 = few papules or vesicles (\< 10) observed on the skin site; Score 2 = more papules or vesicles (≥ 10) observed on \< 50 % of skin site, diffuse or few clusters; Score 3 = many papules or vesicles observed on ≥ 50% of skin site, diffuse or few clusters; Score 4 = many papules or vesicles observed on \> 50% of skin site, with multiple (\> 3) clusters.
| participants | Upper Back | Upper Arm | Side of Torso |
|---|---|---|---|
| 1 hour after patch removal, Placebo, Score >1 | 9 | 6 | 5 |
| 1 hour after patch removal, DTP-System, Score >1 | 7 | 2 | 2 |
| 1 hour after patch removal, Placebo, Score >2 | 2 | 1 | 1 |
| 1 hour after patch removal, DTP-System, Score >2 | 1 | 0 | 0 |
| 24 hours after patch removal, Placebo, Score >1 | 5 | 4 | 4 |
| 24 hours after patch removal, DTP-System, Score >1 | 5 | 2 | 2 |
| 24 hours after patch removal, Placebo, Score >2 | 2 | 1 | 1 |
| 24 hours after patch removal, DTP-System, Score >2 | 0 | 0 | 0 |
| 48 hours after patch removal, Placebo, Score >1 | 5 | 2 | 3 |
| 48 hours after patch removal, DTP-System, Score >1 | 5 | 1 | 1 |
| 48 hours after patch removal, Placebo, Score >2 | 2 | 1 | 1 |
| 48 hours after patch removal, DTP-System, Score >2 | 0 | 0 | 0 |
Other skin effects were assessed according to the following scoring criteria: Score 0 = no other effects observed; Score 1 = slight glazed appearance; Score 2 = marked glazing; Score 3 = glazing with peeling and cracking; Score 4 = glazing with fissures; Score 5 = film of dried serous exudate covering all or part of the patch site; Score 6 = small petechial erosions and/or scabs.
| participants | Upper Back | Upper Arm | Side of Torso |
|---|---|---|---|
| Placebo, Score ≥1 | 10 | 9 | 8 |
| DTP-System, Score ≥1 | 8 | 7 | 8 |
| Placebo, Score =6 | 2 | 6 | 0 |
| DTP-System, Score =6 | 2 | 4 | 2 |
Other skin effects were assessed according to the following scoring criteria: Score 0 = no other effects observed; Score 1 = slight glazed appearance; Score 2 = marked glazing; Score 3 = glazing with peeling and cracking; Score 4 = glazing with fissures; Score 5 = film of dried serous exudate covering all or part of the patch site; Score 6 = small petechial erosions and/or scabs.
| participants | Upper Back | Upper Arm | Side of Torso |
|---|---|---|---|
| 1 hour after patch removal, Placebo, Score ≥1 | 10 | 9 | 8 |
| 1 hour after patch removal, DTP-System, Score ≥1 | 9 | 7 | 8 |
| 1 hour after patch removal, Placebo, Score =6 | 2 | 6 | 0 |
| 1 hour after patch removal, DTP-System, Score =6 | 3 | 4 | 2 |
| 24 hours after patch removal, Placebo, Score ≥1 | 3 | 7 | 3 |
| 24 hours after patch removal, DTP-System, Score ≥1 | 3 | 6 | 3 |
| 24 hours after patch removal, Placebo, Score =6 | 2 | 5 | 1 |
| 24 hours after patch removal, DTP-System, Score =6 | 2 | 3 | 2 |
| 48 hours after patch removal, Placebo, Score ≥1 | 2 | 6 | 1 |
| 48 hours after patch removal, DTP-System, Score ≥1 | 2 | 5 | 2 |
| 48 hours after patch removal, Placebo, Score =6 | 2 | 5 | 1 |
| 48 hours after patch removal, DTP-System, Score =6 | 2 | 3 | 2 |
See Adverse Event section for Safety assessment. Adhesion was assessed according to the following scoring criteria: Score 0 = approximately \> 90% adhered (essentially no lift off the skin); Score 1 = approximately 75% to \< 90% adhered (some edges only lifting off the skin); Score 2 = approximately 50% to \< 75% adhered (less than half of the system lifting off the skin); Score of 3 = approximately \< 50% adhered but not detached (more than half of the system lifting off the skin without falling off); Score of 4 = Patch-system detached (patch /overlay completely off the skin).
| percentage of patients with scores <2 | Upper Back | Upper Arm | Side of Torso |
|---|---|---|---|
| Placebo - Worst adhesion score over 7 days | 89.6 | 93.8 | 93.8 |
| DTP system - Worst adhesion score over 7 days | 83.4 | 89.3 | 85.4 |
| Placebo - Day 1 | 97.9 | 100 | 100 |
| DTP system - Day 1 | 95.8 | 97.9 | 100 |
| Placebo - Day 2 | 100 | 100 | 100 |
| DTP system - Day 2 | 97.8 | 97.8 | 97.9 |
| Placebo - Day 3 | 100 | 97.9 | 100 |
| DTP system - Day 3 | 95.7 | 100 | 95.8 |
| Placebo - Day 4 | 100 | 95.8 | 100 |
| DTP system - Day 4 | 95.6 | 97.7 | 97.8 |
| Placebo - Day 5 | 97.9 | 100 | 100 |
| DTP system - Day 5 | 93.2 | 100 | 93.3 |
| Placebo - Day 6 | 93.5 | 97.8 | 97.9 |
| DTP system - Day 6 | 95.4 | 95.4 | 95.5 |
| Placebo - Day 7 | 91.3 | 97.8 | 95.8 |
| DTP system - Day 7 | 93.1 | 97.6 | 93.0 |
Collected over Adverse event data were collected from the time the patient signed the Informed Consent Form until study discharge (Day 24) (3 days after removal of the last patch).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Systemic Events | — | 1/49 (2%) | 3/49 (6.1%) |
| DTP-system | — | 0/49 (0%) | 14/49 (28.6%) |
| Placebo Patch | — | 0/49 (0%) | 15/49 (30.6%) |
| Event | Systemic Events | DTP-system | Placebo Patch |
|---|---|---|---|
| CoughRespiratory, thoracic and mediastinal disorders | 1/49 | 0/49 | 0/49 |
| Increased upper airway secretionRespiratory, thoracic and mediastinal disorders | 1/49 | 0/49 | 0/49 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 1/49 | 0/49 | 0/49 |
| Event | Systemic Events | DTP-system | Placebo Patch |
|---|---|---|---|
| Application site pruritusGeneral disorders | 0/49 | 14/49 | 15/49 |
| Confusional StatePsychiatric disorders | 3/49 | 0/49 | 0/49 |
| Age, Continuous(Years) | All Participants |
|---|---|
| All Participants | 79.5 ± 6.47 |
| Sex: Female, Male(Participants) | All Participants |
|---|---|
| Female | 29 |
| Male | 20 |
The record gives a start of May 2009, a primary completion of Jun 2009 and a completion of Jun 2009. It does not say whether these dates are actual or estimated.
Results were first posted in Apr 2016, 6 years 10 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Donepezil
Teikoku Pharma USA, Inc.